|
Agenda |
|
|
 |
| Conference Highlights |
Our faculty will include industry and provider experts, as well as key Federal and State officials who help administer the 340B, Medicaid drug rebate, and Medicare Part D programs. The Office of Pharmacy Affairs and other governments agencies will provide presentations and will be available to answer your questions. Topics to be discussed include:
- Special half-day workshop on the basics of the 340B program
- Special half-day workshop on interface between 340B and Medicaid programs
- Government’s proposed changes to the 340B definition of patient
- Eligibility of different patient populations, including employees, nursing home residents, home health patients, prisoners, etc;
- Implications for covered entity partnerships with jails, health departments, and Medicaid programs
- Impact of new drug pricing laws on the 340B and Medicaid drug rebate programs, including the calculation of average manufacturer price and changes to nominal price protections
- Government’s proposed expansion of the number of pharmacies which 340B covered entities may contract to dispense 340B medications
- New opportunities for community pharmacies, chain drug stores, mail order pharmacies, and pharmacy benefit managers to contract with 340B providers;
- The future of alternative method demonstration projects;
- Legislation to expand 340B program to new entities and extend program to inpatients
- Enrollment of children’s hospitals into the program
- President’s proposal to increase funding for OPA and reform the best price calculation used to determine 340B discounts and Medicaid rebates
- Technical guidance on inventory management, stock replacement, patient verification, and audit preparation;
- The future of new and existing 340B case management, disease management, and telemedicine models.
- Increased transparency of 340B calculations affording covered entities a way to identify potential overcharges for the first time;
- Changes to how covered entities have to bill Medicaid for clinic-administered drugs bought through 340B and new rebate obligations for manufacturers;
- Status report on efforts to recover 340B price overcharges, including various legal and legislative action
- Update on the 340B prime vendor program, including new contracts with manufacturers for subceiling discounts
- Efforts to prevent drug diversion, including federal investigations and enforcement
- State and local government partnerships with 340B providers
- Contracting challenges under Medicare Part D, restructured PAP models, and other developments relevant to 340B stakeholders
- Latest news on the future of Patient Assistance Programs
|
|
| |
Conference Attire: Business Casual
Continuing Education Credits for Pharmacists will be Available! |
|
|
Sponsors/
Exhibitors
|
